Zenith Drugs Profile
Key Indicators
- Authorised Capital ₹ 22.40 Cr
as on 08-07-2024
- Paid Up Capital ₹ 17.15 Cr
as on 08-07-2024
- Company Age 23 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 48.19 Cr
as on 08-07-2024
- Satisfied Charges ₹ 12.19 Cr
as on 08-07-2024
- Revenue 25.00%
(FY 2023)
- Profit 51.92%
(FY 2023)
- Ebitda 30.46%
(FY 2023)
- Net Worth 37.98%
(FY 2023)
- Total Assets 46.89%
(FY 2023)
About Zenith Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 22.40 Cr and a paid-up capital of Rs 17.15 Cr.
The company currently has active open charges totaling ₹48.19 Cr. The company has closed loans amounting to ₹12.19 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Zenith Drugs Limited India are Sandeep Bhardwaj as CFO and Sakshi Bhawsar as Company Secretary. Sandeep Bhardwaj, Bhupesh Soni, Ajay Dassundi, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24231MP2000PLC014465
- Company No.
014465
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
15 Nov 2000
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Zenith Drugs Limited offer?
Zenith Drugs Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Respiratory System Drugs, Anti Asthma Drug, Anti Infective Drugs & Medicines, Antifungal Cream, Ointment & Powder, Antibacterial Drugs, Pain Relief Drugs & Pharmaceuticals, Pain Reliever Gel, Common Disease Medicines.
Who are the key members and board of directors at Zenith Drugs?
Executive Team (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Sandeep Bhardwaj | Managing Director | 31-Oct-2003 | Current |
Sakshi Bhawsar | Company Secretary | 16-Sep-2023 | Current |
Board Members(5)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Anil Malik | Director | 25-Sep-2023 | Current |
Ajay Dassundi | Director | 31-Oct-2003 | Current |
Bhupesh Soni | Director | 15-Mar-2001 | Current |
Ranjana Sehgal | Director | 16-Sep-2023 | Current |
Deendayal Kumawat | Director | 25-Sep-2023 | Current |
Financial Performance and Corporate Structure Insights of Zenith Drugs.
Zenith Drugs Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 25% increase. The company also saw a substantial improvement in profitability, with a 51.92% increase in profit. The company's net worth Soared by an impressive increase of 37.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Zenith Drugs?
In 2023, Zenith Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
My Med Private Limited
Active 3 years 8 monthsSandeep Bhardwaj, Bhupesh Soni and 1 more are mutual person
Charges (Loans)
Lender | Amount | Status |
---|---|---|
Others Creation Date: 16 Jun 2023 | ₹10.00 Cr | Open |
Others Creation Date: 02 Feb 2023 | ₹10.00 Cr | Open |
Hdfc Bank Limited Creation Date: 30 Apr 2022 | ₹2.45 M | Open |
How Many Employees Work at Zenith Drugs?
Zenith Drugs has a workforce of 99 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zenith Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zenith Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.